Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.27)
# 4,160
Out of 4,876 analysts
7
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $29.96 | +60.21% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $7.45 | +302.68% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $68.37 | +14.09% | 1 | Aug 3, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $14.33 | +179.13% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $1.02 | +2,154.90% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $29.96
Upside: +60.21%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $7.45
Upside: +302.68%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $68.37
Upside: +14.09%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $14.33
Upside: +179.13%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $1.02
Upside: +2,154.90%